Scoreboard / CRNX
Crinetics Pharmaceuticals CRNX
Setup Snapshot
The Setup in One Card
How CRNX moved and the catalyst behind the move, from its Issue No. 03 write-up. It is not on the current Scoreboard, so it carries no Friday Five Score this week.
Issue No. 03
Original Pick
Sector Trend
Neutral-0.23%
Covered In
Issue No. 03 · July 10, 2026
Catalyst
AcquisitionVertex agreed to acquire it for roughly $10B at $85 per share in cash
Return measured from the Thursday, July 2 close to the Thursday, July 9 close, the week it appeared in Issue No. 03.
Why It Moved
The Story Behind the Move
Catalyst
Vertex agreed to acquire it for roughly $10B at $85 per share in cash
Why It Mattered
Cash deals from large, well funded acquirers close far more often than not, so the stock immediately repriced to just below the offer and parked there. From here it is a merger arbitrage position, not a growth story.
Risk Note
The upside is capped near $85 unless a rival bid appears, and if the deal breaks on regulatory review the stock likely falls back toward the low 40s where it traded before the offer.
Reader Takeaway
When a cash buyout lands, the gain is banked almost instantly. Chasing the stock afterward buys a small, capped reward against a large, low probability loss.
This page is for educational and informational purposes only. It is not financial advice, investment advice, or a recommendation to buy or sell any security.